This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Addressing Cognition in Geriatric Depression: Measurement- and Evidence-Based  Care Strategies

Addressing Cognition in Geriatric Depression: Measurement- and Evidence-Based Care Strategies



Time to Complete

1.50 hours


May 18, 2016


May 17, 2017
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Provided by The American Association for Geriatric Psychiatry

Commercial Supporter

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.


Produced by Haymarket Medical Education (HME)

Program Description

In this recording of a live symposium for geriatric psychiatrists that took place on March 8, 2016 in Washington, DC, three leading experts explore the challenges that complicate the treatment of geriatric patients with MDD. The content of the program centers on cognitive symptoms of depression, use of measurement-based care in MDD treatment, and clinical trial data on newer agents/strategies shown to positively impact cognition. Guidance for the implementation of shared decision-making is provided via an on-stage, panel interview of an actual geriatric patient with MDD, who shares his experiences with diagnosis and treatment.

Intended Audience

Psychiatrists and psychiatric allied health professionals

Educational Objectives

At the conclusion of this program, participants should be better able to:

  • Describe the link between untreated symptoms of depression—particularly cognitive deficits—and dementia in geriatric patients with major depressive disorder (MDD)
  • Implement individualized treatment strategies for geriatric patients with MDD
  • Increase the proportion of patients with MDD aged 65 years and older whose symptoms are reassessed using a validated, quantitative assessment tool within 3 months of initiating antidepressant therapy
  • Utilize motivational interviewing and other strategies to actively engage geriatric patients with MDD in their treatment plans

Conflict Of Interest Disclosure Policy

As an ACCME-accredited provider, the American Association for Geriatric Psychiatry must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in an American Association for Geriatric Psychiatry activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.


David C. Steffens, MD, MHS (Chair)
Professor and Chair, Department of Psychiatry
University of Connecticut Health Center School of Medicine
Farmington, CT

Dr. Steffens is a consultant to Janssen Research & Development, LLC, and receives research support from the National Institute of Mental Health (NIMH) and textbook royalties from American Psychiatry Press, Inc.

J. Craig Nelson, MD
Leon J. Epstein Professor of Geriatric Psychiatry
Director of Geriatric Psychiatry
University of California, San Francisco
San Francisco, CA

Dr. Nelson is a consultant for Corcept, Janssen, Lundbeck, and Otsuka and an advisor for Otsuka and Sunovion. He has received honoraria from Otsuka (Asia), Bristol-Myers Squibb (Canada), and Lundbeck. He has provided research support for Avid and NIMH and owns stock in Atossa Genetics.

Charles Raison, MD
Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families
Professor, Human Development and Family Studies
School of Human Ecology, University of Wisconsin-Madison
Professor, Department of Psychiatry
School of Medicine and Public Health, University of Wisconsin-Madison
Madison, WI

Dr. Raison is a consultant for Otsuka and Pamlab. He serves on the speakers’ bureaus for Otsuka, Pamlab, and Sunovion. Dr. Raison’s spouse is an employee of Transdermal Therapeutics.

Accredited Provider Disclosure

Chris Wood, of the American Association for Geriatric Psychiatry (AAGP), has no relevant financial relationships to disclose.

Planners' and Managers' Disclosures

Susan Basilico and Krista Sierra of Haymarket Medical Education have nothing to disclose with regard to commercial support.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Association for Geriatric Psychiatry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The American Association for Geriatric Psychiatry designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Takeda, Lundbeck, AAGP, and HME do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Takeda, Lundbeck, AAGP, and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you have any questions relating to the accreditation of this activity, please contact


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue